CSL Receives FTC Request for Additional Information
CSL Receives FTC Request for Additional Information
Melbourne, Australia — 13/10/2008
CSL Receives FTC Request for Additional Information on its Proposed Merger with Talecris Biotherapeutics.
CSL Limited today announced that it has received a request for additional information, commonly referred to as a Second Request, from the U.S. Federal Trade Commission (“FTC”) regarding its proposed acquisition of Talecris Biotherapeutics, which was announced on August 13, 2008.
Download this release:
CSL Receives FTC Request
For further information, please contact:
Media ContactsDr Rachel David
Director of Public Affairs
Phone: 0401 775 779
Investor ContactMark Dehring
Director of Investor Relations
Phone: +61 3 9389 2818
Email:
mark.dehring@csl.com.au